SCHEMBL3754728

SCHEMBL3754728

CC(C)(C)N(C(=O)O)C1CCN(c2ccc(N)cc2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GFER P55789 4/20 0.50
CASP6 P55212 1/20 0.50
USP2 O75604 2/20 0.42
MAPT P10636 6/20 0.41
GAA P10253 4/20 0.41
ALDH1A1 P00352 4/20 0.41
KDM4E B2RXH2 3/20 0.41
KMT2A Q03164 2/20 0.41
ADRA2C P18825 1/20 0.41
PTK2B Q14289 1/20 0.41
ESR2 Q92731 1/20 0.41
HTT P42858 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
MEN1 O00255 1/20 0.39
NPC1 O15118 1/20 0.39
TP53 P04637 1/20 0.39
POLB P06746 1/20 0.39
THRB P10828 1/20 0.39
ALOX15 P16050 1/20 0.39
RECQL P46063 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18128887 0.83 GCK (0.42) USP2NOTUM
SCHEMBL17959086 0.83 USP2 (0.40) GFERCASP6USP2ALDH1A1KMT2A
SCHEMBL17994179 0.82 MAPT (0.55) MAPTALDH1A1KMT2AMEN1POLB
SCHEMBL3123617 0.81 GFER (0.50) GFERCASP6USP2MAPTGAA
SCHEMBL517947 0.80 LGMN (0.40) MAPTALDH1A1ADRA2CRORC
SCHEMBL1353798 0.80 GFER (0.43) GFERCASP6USP2MAPTGAA
SCHEMBL16570049 0.80 GFER (0.47) GFERCASP6USP2MAPTGAA
SCHEMBL2384977 0.79 CHRM4 (0.43) GFERCASP6USP2MAPTGAA
SCHEMBL1534427 0.78 NOTUM (0.55) NOTUMNPY5R
SCHEMBL2002304 0.78 CHRM4 (0.45) MAPTNOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9421205-B2 FAK inhibitors Cancer Therapeutics CRC Pty Ltd. (AU) 2016-08-23 US disclosed
US-9187465-B2 Oxazole tyrosine kinase inhibitors SAREUM LIMITED (GB) 2015-11-17 US disclosed
US-20150057282-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2015-02-26 US disclosed
US-8921544-B2 Oxazole tyrosine kinase inhibitors SAREUM LIMITED (GB) 2014-12-30 US disclosed
US-20140275041-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2014-09-18 US disclosed
US-20130102592-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2013-04-25 US disclosed
US-8378095-B2 Oxazole tyrosine kinase inhibitors Saruem Limited (GB) 2013-02-19 US disclosed
US-20100298301-A1 OXAZOLE TYROSINE KINASE INHIBITORS SAREUM LIMITED (GB) 2010-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140275041-A1 OXAZOLE TYROSINE KINASE INHIBITORS FLT3, AURKA, FLT1 GFER 2699/4885CASP6 3335/4885USP2 3667/4885
US-20100298301-A1 OXAZOLE TYROSINE KINASE INHIBITORS FLT3, AURKA, FLT1 GFER 2699/4885CASP6 3335/4885USP2 3667/4885
US-20150057282-A1 OXAZOLE TYROSINE KINASE INHIBITORS FLT3, AURKA, FLT1 GFER 2699/4885CASP6 3335/4885USP2 3667/4885
US-20130102592-A1 OXAZOLE TYROSINE KINASE INHIBITORS FLT3, AURKA, FLT1 GFER 2638/4885CASP6 3430/4885USP2 3673/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.